In assays with U87MG glioma cells, which depend upon MT1-MMP for activation of MMP-2, the MT1-MMP-selective N-TIMP-2 variant was uniquely able to reduce the activation of MMP-2 by up to 50% (Arkadash et al., 2018). Here, MMP2 is linked to central nervous system cancer.